- Home
- PZZA vs GERN Comparison
PZZA vs GERN Comparison
Compare PZZA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZZA
- GERN
- Stock Information
- Founded
- PZZA 1984
- GERN 1990
- Country
- PZZA United States
- GERN United States
- Employees
- PZZA N/A
- GERN N/A
- Industry
- PZZA Restaurants
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- PZZA Consumer Discretionary
- GERN Health Care
- Exchange
- PZZA Nasdaq
- GERN Nasdaq
- Market Cap
- PZZA 1.5B
- GERN 1.5B
- IPO Year
- PZZA 1993
- GERN 1996
- Fundamental
- Price
- PZZA $41.01
- GERN $1.48
- Analyst Decision
- PZZA Buy
- GERN Buy
- Analyst Count
- PZZA 12
- GERN 11
- Target Price
- PZZA $55.55
- GERN $5.80
- AVG Volume (30 Days)
- PZZA 1.1M
- GERN 14.6M
- Earning Date
- PZZA 05-08-2025
- GERN 05-07-2025
- Dividend Yield
- PZZA 4.49%
- GERN N/A
- EPS Growth
- PZZA 2.42
- GERN N/A
- EPS
- PZZA 2.54
- GERN N/A
- Revenue
- PZZA $2,059,387,000.00
- GERN $76,994,000.00
- Revenue This Year
- PZZA $3.43
- GERN $208.83
- Revenue Next Year
- PZZA $3.43
- GERN $57.49
- P/E Ratio
- PZZA $16.15
- GERN N/A
- Revenue Growth
- PZZA N/A
- GERN 32386.92
- 52 Week Low
- PZZA $35.28
- GERN $1.45
- 52 Week High
- PZZA $66.42
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- PZZA 42.20
- GERN 32.42
- Support Level
- PZZA $39.28
- GERN $1.63
- Resistance Level
- PZZA $42.21
- GERN $1.62
- Average True Range (ATR)
- PZZA 1.83
- GERN 0.11
- MACD
- PZZA -0.36
- GERN 0.02
- Stochastic Oscillator
- PZZA 21.82
- GERN 6.82
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.